The pathobiology of pulmonary hypertension: Endothelium

Clinics in Chest Medicine

Volumn 22, Issue 3, 2001, Pages 405-418

  Tuder, Rubin M ^a   Cool, Carlyne D ^a   Yeager, Michael ^a   Taraseviciene Stewart, Laimute ^a   Bull, Todd M ^b   Voelkel, Norbert F ^b  

^a Division of Pulmonary   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTACYCLIN SYNTHASE; PROTEIN BAX; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

BLOOD CLOTTING; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM; ENDOTHELIUM CELL; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ARTERY; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

EID: 0034808856     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-5231(05)70280-X     Document Type: Article

References (57)

1. Coagulation and fibrinolytic parameters in patients with pulmonary hypertension
2. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization
3. Isolation and characterization of neutralizing monoclonal antibodies to human vascular endothelial growth factor/vascular permeability factor121 (VEGF/VPF121)
4. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial
5. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
6. The histopathology of 36 cases of plexogenic pulmonary arteriopathy
7. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension
8. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection
9. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell specific markers: Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth
10. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene
11. Multiple mutation analyses in single tumor cells with improved whole genome amplification
12. Nitric oxide- an endothelial cell survival factor
13. Attenuated hypoxic pulmonary hypertension in mice lacking the 5- hydroxytryptamine transporter gene
14. The pulmonary circulation of mice with either homozygous or heterozygous disruption of endothelial nitric oxide synthase is hyperresponsive to chronic mild hypoxia
15. A role for the serotonin transporter in hypoxia-induced pulmonary hypertension
16. Prothrombotic mechanisms in primary pulmonary hypertension
17. Selective pulmonary prostacyclin synthase overexpression in transgenic mice protects against the development of hypoxic pulmonary hypertension
18. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension
19. Expression of endothelin- 1 in the lungs of patients with pulmonary hypertension
20. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src
21. Prostacyclin receptor-dependent alteration of the lung gene expression pattern and modulation of pulmonary vascular remodeling
22. Transfection of inducible mitric oxide synthase gene causes apoptosis in vascular smooth muscle cells
23. Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension
24. BMP2-induced apoptosis is mediated by activation of the TAK1-p38 kinase pathway that is negatively regulated by Smad6
25. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension
26. Genetic instability occurs in the majority of young patients with colorectal cancer
27. Endothelial dysfunction in pulmonary hypertension
28. High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension
29. Genomic instability in the type II TGF-beta1 receptor gene in atherosclerotic and restenotic vascular cells
30. Transcriptional and translational regulation of inflammatory mediator production by endogenous TGF-beta in macrophages that have ingested apoptotic cells
31. Pulmonary hypertension: Newer concepts in diagnosis and management
32. Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32
33. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32
34. Discrimination between multicentric and multifocal carcinomas of the breast through clonal analysis
35. Prostacyclin can inhibit DNA synthesis in vascular smooth muscle cells
36. Primary pulmonary hypertension
37. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF
38. Tissue factor expression by endothelial cells in sickle cell anemia
39. Sickle cell anemia as a possible state of enhanced anti-apoptotic tone: Survival effect of vascular endothelial growth factor on circulating and unanchored endothelial cells
40. Circulating activated endothelial cells in sickle cell anemia
41. Role of vascular injury and hemodynamics in rat pulmonary artery remodeling
42. Inhibition of the VEGF receptor-2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension
43. Heterozygous germline mutations in BMPR2 encoding a TGF-β receptor cause familiar pulmonary hypertension
44. Pulmonary hypertension and inflammation
45. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: Evidence for a process of disordered angiogenesis
46. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension
47. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension
48. Monoclonal endothelial cells in appetite suppressant-associated pulmonary hypertension
49. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension
50. Severe pulmonary hypertensive diseases: A perspective
51. Hypoxia-induced pulmonary vascular remodeling - A model for what human disease?
52. Primary pulmonary hypertension between inflammation and cancer
53. Hypoxia inhibits gene expression of voltage-gated K + channel alpha subunits in pulmonary artery smooth muscle cells
54. 5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension
55. Mutational analysis of endothelial cell TGF-β receptor type II in plexiform lesions of patients with primary pulmonary hypertension
56. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1 alpha
57. cGMP-elevating agents supress proliferation of vascular smooth muscle cells by inhibiting the activation of epidermal growth factor signaling pathway